Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine (Nasdaq: PRME) has dosed the first patient in its global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease. This is the company’s first clinical study of a gene-editing therapy delivered inside the body and the first clinical evaluation of its liver franchise. PM577a is designed as a one-time treatment to correct the H1069Q mutation in the ATP7B gene.
The open-label, first-in-human study evaluates safety, tolerability and preliminary efficacy across ascending doses in adults and adolescents with at least one p.H1069Q allele, initially enrolling clinically stable adults on standard therapy. Prime Medicine expects initial clinical data in 2027. The FDA granted Rare Pediatric Disease designation to PM577 for Wilson disease. The company also described a follow-on candidate designed to correct the R778L mutation.
Prime Medicine (PRME) received U.S. FDA clearance for PM647's investigational new drug application on September 24, 2026. The clearance allows clinical study to proceed initially in the United States. PM647 is an investigational in vivo Prime Editor designed to correct the PiZZ genotype in alpha-1 antitrypsin deficiency (AATD). Approximately 100,000 people in the United States carry that genotype.
The planned global Phase 1/2 study is a first-in-human, single-arm, open-label trial assessing safety, tolerability and preliminary clinical efficacy across ascending doses of a one-time intravenous infusion. Enrollment will start with adults who have lung-only AATD. A separate cohort with significant liver disease, with or without lung manifestations, will be added after tolerability is demonstrated in the lung-only group. Prime Medicine expects initial clinical data in 2027.
Prime Medicine (PRME) will participate in three investor and healthcare conferences in September 2026, featuring 1x1 investor meetings and fireside chats in Boston and New York.
Management will host 1x1 meetings at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, in Boston, MA. The company will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 9:30 a.m. ET, and another fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2026, at 10:00 a.m. ET, both in New York, NY.
Live audio webcasts of the fireside chats will be available in the News & Events section of Prime Medicine’s website under “Events & Presentations,” with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME) reported second quarter 2026 results and pipeline progress, including IND and CTA clearances in the U.S. and New Zealand for PM577a in Wilson disease, establishing a global Phase 1/2 trial with startup underway and initial clinical data expected in 2027.
The company obtained a favorable, binding arbitration outcome with Beam Therapeutics affirming Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency and plans an IND/CTA filing in 3Q 2026. The FDA granted RMAT designation to PM359 in chronic granulomatous disease, and Prime Medicine is engaging toward a potential BLA submission in 1H 2027. R&D expenses fell to $33.4 million, G&A to $11.0 million, and net loss narrowed to $42.1 million. Cash, cash equivalents, investments, and restricted cash totaled $108.8 million as of June 30, 2026, which Prime Medicine expects will fund operations into 2027.
Prime Medicine (Nasdaq: PRME) announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD). This clearance allows PM577a to proceed to clinical study in the United States.
Combined with a previously cleared Clinical Trial Application in New Zealand, the IND supports a global Phase 1/2, first-in-human, open-label trial in adults and adolescents with WD carrying the H1069Q mutation in the ATP7B gene, a prevalent WD-causing allele in North America and Europe. The trial will assess safety, tolerability, biological activity and efficacy across ascending doses, with planned evaluations including copper-related biomarkers and hepatic copper by biopsy. Trial initiation is expected in the second half of 2026, with initial clinical data anticipated in 2027.
Prime Medicine (Nasdaq: PRME) reported a binding arbitration win against Beam Therapeutics regarding PM647 for Alpha-1 Antitrypsin Deficiency (AATD).
The tribunal confirmed PM647 is within Prime Medicine’s contractual field, found no breach, and awarded no damages. Prime plans an IND/CTA for PM647 in Q3 2026, with initial clinical data in 2027.
Prime Medicine (Nasdaq: PRME) received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for PM359, an investigational autologous Prime Edited stem cell therapy for p47phox-deficient chronic granulomatous disease (CGD).
The RMAT decision, based on Phase 1/2 data in two patients, adds to Fast Track, Orphan Drug, and Rare Pediatric Disease designations and enables intensive FDA interaction plus eligibility for rolling and priority BLA review.
Prime Medicine (Nasdaq: PRME) received New Zealand Medsafe clearance for a Clinical Trial Application for PM577a, an investigational in vivo Prime Editing therapy targeting the H1069Q ATP7B mutation in Wilson Disease.
This first clinical authorization for Prime Medicine’s in vivo Prime Editing enables a global open-label Phase 1/2 trial, expected to start in the second half of 2026, with initial data anticipated in 2027.
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET in Miami Beach, FL.
A live audio webcast and 90-day replay will be available in the News & Events section of Prime Medicine’s website.
Prime Medicine (Nasdaq: PRME) announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET in New York.
A live audio webcast and a 90-day replay will be available in the News & Events section of the company’s website.